In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone
- PMID: 2013510
- DOI: 10.1007/BF01643761
In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone
Abstract
We compared the in-vitro activity of cefoperazone-sulbactam (2:1), other beta-lactams, amino-glycosides and ciprofloxacin against cefoperazone-susceptible and -resistant nosocomial gram-negative bacilli. Resistant isolates including Pseudomonas aeruginosa were susceptible to cefoperazone-sulbactam; the susceptible isolates had modestly increased susceptibility to the combination. Sulbactam, by itself, was poorly active. Among others tested, ciprofloxacin and imipenem were the most active. No inoculum effect was seen with cefoperazone-sulbactam and this drug combination had a prolonged post-antibiotic effect. Cefoperazone-sulbactam is an attractive candidate for evaluation in the treatment of nosocomial infections due to aerobic gram-negative bacilli.
Similar articles
-
[Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].Zhonghua Yi Xue Za Zhi. 2003 Mar 10;83(5):385-90. Zhonghua Yi Xue Za Zhi. 2003. PMID: 12820914 Chinese.
-
The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.J Microbiol Immunol Infect. 2018 Apr;51(2):207-213. doi: 10.1016/j.jmii.2017.08.026. Epub 2017 Oct 6. J Microbiol Immunol Infect. 2018. PMID: 29037802
-
The susceptibility of non-fermentative Gram-negative bacilli to cefperazone and sulbactam compared with other antibacterial agents.Int J Antimicrob Agents. 2003 Oct;22(4):444-8. doi: 10.1016/s0924-8579(03)00109-2. Int J Antimicrob Agents. 2003. PMID: 14522108
-
Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria?Infect Genet Evol. 2021 Mar;88:104707. doi: 10.1016/j.meegid.2021.104707. Epub 2021 Jan 5. Infect Genet Evol. 2021. PMID: 33418147 Review.
-
beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.Clin Infect Dis. 1997 Mar;24(3):494-7. doi: 10.1093/clinids/24.3.494. Clin Infect Dis. 1997. PMID: 9114205 Review.
Cited by
-
Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.Drugs. 1996 Jun;51(6):1019-74. doi: 10.2165/00003495-199651060-00010. Drugs. 1996. PMID: 8736621 Review.
-
Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistant Pseudomonas aeruginosa and Escherichia coli in granulocytopenic mice.Antimicrob Agents Chemother. 1993 Sep;37(9):1927-30. doi: 10.1128/AAC.37.9.1927. Antimicrob Agents Chemother. 1993. PMID: 8239607 Free PMC article.
References
-
- Rev Infect Dis. 1988 Jan-Feb;10 Suppl 1:S57-63 - PubMed
-
- Diagn Microbiol Infect Dis. 1984 Jun;2(3):255-60 - PubMed
-
- Diagn Microbiol Infect Dis. 1985 Nov;3(6):489-99 - PubMed
-
- Diagn Microbiol Infect Dis. 1989 Jul-Aug;12(4 Suppl):165S-169S - PubMed
-
- Antimicrob Agents Chemother. 1988 Apr;32(4):503-9 - PubMed